Bone-targeting agents in prostate cancer

Daniel L. Suzman, Sosipatros A. Boikos, Michael A. Carducci

Research output: Contribution to journalReview article

Abstract

Bone metastases are present in the vast majority of men with advanced prostate cancer, representing the main cause for morbidity and mortality. Recurrent or metastatic disease is managed initially with androgen deprivation but the majority of the patients eventually will progress to castration-resistant prostate cancer, with patients developing bone metastases in most of the cases. Survival and growth of the metastatic prostate cancer cells is dependent on a complex microenvironment (onco-niche) that includes the osteoblasts, the osteoclasts, the endothelium, and the stroma. This review summarizes agents that target the pathways involved in this complex interaction between prostate cancer and bone microenvironment and aim to transform lethal metastatic prostate cancer into a chronic disease.

Original languageEnglish (US)
Pages (from-to)619-628
Number of pages10
JournalCancer and Metastasis Reviews
Volume33
Issue number2-3
DOIs
StatePublished - Sep 2014

Keywords

  • Bone metastases
  • Bone-targeting agents
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bone-targeting agents in prostate cancer'. Together they form a unique fingerprint.

  • Cite this